DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Controlled Release of Inactivated Chikungunya Virus Vaccine Candidate: A Single Vaccination Approach for Long-Term Immunity
[Technical Report, Annual Report]
HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE BETHESDA MD
Pagination or Media Count:
Requirement of multi dose regimen of vaccines presents a barrier to protect from vaccine preventable disease. Problem is amplified in case of emerging infectious viruses where either there is a lack of live attenuated strain of virus to immunize and for inactivated vaccine not much time is at hand to perform multiple immunizations. Chikungunya virus CHIKV has caused large outbreak in tropical countries across the globe. There is no FDA approved vaccine against CHIKV. In this study gamma-radiation inactivated CHIK18125 is encapsulated in lipid nanoparticles HALNP which will be embedded in the polyelectrolyte multilayer PEM films for temporal release in vivo. This platform will provide a single-shot vaccine of inactivated-CHIKV18125 for intermittent release of antigen mimicking primary and booster regimen of multi-dose vaccination.CHIKV18125 was inactivated by gamma radiation using a unique approach of protecting viral proteins while allowing for homogenous inactivation of the virus. Protection of epitopes on inactivated-CHIKV18125 was determined and encapsulation of inactivated-CHIKV18125 in HALNP was performed. Mice were immunized with HALNP encapsulated inactivated-CHIKV18125 and anti-CHIKV antibody titers were evaluated to establish antigen preservation post encapsulation. Experiments are now planned to test the long-term immunity following immunization with HALNP-encapsulated inactivated CHIKV18125 embedded in the PEM lattice. This study addresses an FY17 PRMRP topic Vaccine Development for Infectious Disease and Area of Encouragement under Development of vaccines to prevent U.S. Service members from becoming ill from endemic disease exposure during operational deployments including arthropod-borne diseases such as chikungunya virus
[A, Approved For Public Release]